Sign In
Buy CRSP
$52.08
+0.0600 (+0.115%)
At Close: Jun 03, 2026
CRISPR Therapeutics AG (CRSP) Gains As Market Dips: What You Should Know
06:48pm, Friday, 18'th Jun 2021
In the latest trading session, CRISPR Therapeutics AG (CRSP) closed at $127.83, marking a +0.44% move from the previous day.
Why demand for CRISPR gene editing is increasing
02:48pm, Thursday, 17'th Jun 2021
CNBC's Meg Tirrell discusses CRISPR gene editing with one of its inventors, Jennifer Doudna, UC Berkeley biochemist.
Jim Cramer Thinks Powell Got It Right and Offers a Few Top Picks
08:10am, Thursday, 17'th Jun 2021
All the major indexes pulled back on again Wednesday, and again the Nasdaq led the charge lower.
CRISPR (CRSP) Inks Deal for Gene Therapies in Neurological Diseases
12:02pm, Wednesday, 16'th Jun 2021
CRISPR Therapeutics (CRSP) signs a strategic collaboration with Capsida Biotherapeutics to develop/commercialize gene editing therapies for neurological diseases.
CRISPR Therapeutics, Capsida Collaborate To Develop Gene-Edited Therapies For Neurological Diseases
08:06am, Tuesday, 15'th Jun 2021
CRISPR Therapeutics (NASDAQ: CRSP) has signed a deal with Capsida Biotherapeutics, a gene therapy player specializing in AAV engineering, to carve out a delivery mechanism for the company's gene-e
- Collaboration leverages expertise and capabilities of both companies towards developing life-changing treatments for severe neurological diseases -
Despite A 26% Growth Over The Last Month CRISPR Stock May Continue To Rise
06:30am, Tuesday, 15'th Jun 2021
The stock price of CRISPR Therapeutics, a biotechnology gene editing company focused on developing gene-based medicines for human diseases, has seen a solid 26% rise over the last twenty-one trading s
CRISPR (CRSP) Up on Positive New Gene Therapy CTX001 Data
12:02pm, Monday, 14'th Jun 2021
CRISPR Therapeutics' (CRSP) gene-editing therapy, CTX001, shows consistent and sustained response to treatment in patients with transfusion-dependent beta thalassemia and sickle cell disease.
Monday's Analyst Upgrades and Downgrades: Chipotle, CRISPR, Hess Midstream, iMedia, Kinder Morgan, Wendy's and More
09:17am, Monday, 14'th Jun 2021
Monday's futures were relatively flat, with the Nasdaq looking the best out of the group with about a 0.2% gain.
Vertex, Crispr Unveil More Encouraging Data From Sickle Cell, Thalassemia Gene Therapy Trials
10:33am, Friday, 11'th Jun 2021
Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) and Crispr Therapeutics AG (NASDAQ: CRSP) have announced new data from Phase 1/2 clinical trials evaluating CTX001 in beta-thalassemia and sickl
CRISPR Therapeutics AG (CRSP) Stock Sinks As Market Gains: What You Should Know
06:48pm, Tuesday, 08'th Jun 2021
CRISPR Therapeutics AG (CRSP) closed the most recent trading day at $118.91, moving -0.24% from the previous trading session.
CRISPR Therapeutics AG (CRSP) Presents at Goldman Sachs 42nd Annual Global Healthcare Broker Conference Call - (Transcript)
05:28pm, Tuesday, 08'th Jun 2021
CRISPR Therapeutics AG (CRSP) Presents at Goldman Sachs 42nd Annual Global Healthcare Broker Conference Call - (Transcript)
How Much Will the Nkarta Deal Help CRISPR Therapeutics?
12:16pm, Sunday, 06'th Jun 2021
Unfortunately, this isn't an endorsement by a big drug developer.
CRISPR Therapeutics AG (CRSP) Stock Sinks As Market Gains: What You Should Know
06:48pm, Wednesday, 02'nd Jun 2021
CRISPR Therapeutics AG (CRSP) closed the most recent trading day at $114.74, moving -0.92% from the previous trading session.
CRISPR Therapeutics AG (CRSP) CEO Sam Kulkarni Presents at Jefferies Virtual Healthcare Conference (Transcript)
03:47pm, Tuesday, 01'st Jun 2021
CRISPR Therapeutics AG (CRSP) CEO Sam Kulkarni Presents at Jefferies Virtual Healthcare Conference (Transcript)
